INOVIO PHARMACEUTICALS, INC. Fair Value Adjustment of Warrants
INOVIO PHARMACEUTICALS, INC. (INO) reported Fair Value Adjustment of Warrants of -$13.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$13.87M, a 838.47% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$4.14M.
- INOVIO PHARMACEUTICALS, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$21.17M.
- INOVIO PHARMACEUTICALS, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was $22.52M.
- INOVIO PHARMACEUTICALS, INC. fair value adjustment of warrants for fiscal 2025 was -$493.23K.
- INOVIO PHARMACEUTICALS, INC. fair value adjustment of warrants for fiscal 2024 was -$2.81M.
- INOVIO PHARMACEUTICALS, INC. fair value adjustment of warrants for fiscal 2023 was $0.00.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.87M 10-Q · filed 2026-08-12 | -$18.01M 10-Q · filed 2026-08-12 | -$39.18M derived: sum of 3 quarters · filed 2026-08-12 | -$16.66M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$4.14M 10-Q · filed 2026-05-13 | -$25.31M derived: sum of 2 quarters · filed 2026-05-13 | -$2.80M derived: sum of 3 quarters · filed 2026-05-13 | -$918.06K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$21.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.34M derived: sum of 2 quarters · filed 2026-03-12 | $3.22M derived: sum of 3 quarters · filed 2026-08-12 | -$493.23K 10-K · filed 2026-03-12 |
| 2025-09-30 | $22.52M 10-Q · filed 2025-11-10 | $24.39M derived: sum of 2 quarters · filed 2026-08-12 | $20.68M 10-Q · filed 2025-11-10 | $17.87M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.88M 10-Q · filed 2026-08-12 | -$1.83M 10-Q · filed 2026-08-12 | -$4.64M derived: sum of 3 quarters · filed 2026-08-12 | -$4.64M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$3.71M 10-Q · filed 2026-05-13 | -$6.52M derived: sum of 2 quarters · filed 2026-05-13 | -$6.52M derived: sum of 3 quarters · filed 2026-05-13 | -$6.52M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.81M derived: sum of 2 quarters · filed 2026-03-12 | -$2.81M derived: sum of 3 quarters · filed 2026-03-12 | -$2.81M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |